Contact Us
Menu
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Events
News
Posts
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Events
News
Posts

Bispecific ADCs YH012, YH013

Home Preclinical & Clinical Assets Bispecific ADCs YH012, YH013

YH012 and YH013 are two bispecific ADCs developed using our RenLite platform, which are intended for the treatment of solid tumor. YH012 and YH013 are currently at the discovery stage.

AACR 2022 poster: YH012, a Novel Bispecific Anti-HER2 and TROP2 Antibody-Drug Conjugate, Exhibits Potent Antitumor Efficacy

Contact us for partnership: [email protected]

Related Resources

News

Back to top